Safety Concern. Synthetic Opioids With the addition of testing of four (4) synthetic opioids to the drug testing panel, the Medical Review Officer (MRO) will contact the employee to request a valid prescription if one of the opioids is found in the test results. The employee will have five (5) days to supply a valid prescription. Upon receipt of a valid prescription, the MRO will then determine the test to be negative, and if a safety concern remains, will provide a statement to the employer of the safety concern. If the employee fails to submit a valid prescription within 5 days, the test result will be deemed positive. When a safety concern is issued by the MRO, the employee must no longer drive, and must be evaluated by the District’s medical examiner. The employee will be asked to make contact with their prescribing physician. The prescribing physician should be willing to state to the MRO and District’s medical examiner that the employee can safely perform their safety-sensitive functions while taking the medication(s), or consider changing the employee’s medication to one that doesn’t make the employee medically unqualified or does not pose a significant safety risk. The employee’s medical exam certificate (MEC) will be revoked following the safety concern until such time as the employee is medically cleared to return to driving. Failure to obtain medical clearance within a 30-day period will result in the employee being referred to the School Board for termination.
Safety Concern. Synthetic Opioids (cont’d) When a safety concern is issued by the MRO, the employee must no longer drive, and must be evaluated by the District’s medical examiner. The employee will be asked to make contact with their prescribing physician. The prescribing physician should be willing to state to the MRO and District’s medical examiner that the employee can safely perform their safety-sensitive functions while taking the medication(s), or consider changing the employee’s medication to one that does not make the employee medically unqualified or does not pose a significant safety risk. The employee’s medical exam certificate (MEC) will be revoked following the safety concern until such time as the employee is medically cleared to return to driving. Failure to obtain medical clearance within a 30-day period will result in the employee being referred to the School Board for termination.
Safety Concern. The Affiliate shall immediately notify the School in writing of any situation or behavior involving any Student or any of School's Program faculty members that: (I) are deemed by the Affiliate to pose a significant, credible, or specific threat of xxxx to any person, including the Affiliate's patients or staff or (2) may jeopardize the ability or capability of the School or the Affiliate to perfonn or meet their obligations under this Agreement.
Safety Concern. An employee shall not be subject to disciplinary action for the employee's refusal to operate or handle any piece of equipment or work in a work situation that the employee believes will place them in imminent danger of injury. If it is later proven that the employee's objection was unfounded, the City can take disciplinary action for the employee's refusal to perform their duties.
Safety Concern. (a) Notwithstanding anything in this Agreement to the contrary, ImmunoGen, as sponsor of the clinical trials to be conducted under each Development Plan under this Agreement, shall have the unilateral right to terminate any clinical trial conducted under this Agreement immediately for good faith safety concerns. ImmunoGen shall provide written notice to Jazz upon termination of any clinical trial conducted pursuant to this Agreement. Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Safety Concern. Notwithstanding anything to the contrary herein or in the applicable DT Co-Co Plan for a given DT Co-Co Program, if, at any time during or after the Term of such DT Co-Co Program, Moderna reasonably believes that there is a Safety Concern with respect to a Product in such DT Co-Co Program, then Moderna will immediately (and in any event within five (5) Business Days after the date it determines there is a Safety Concern) provide written notice to Metagenomi of such Safety Concern, following which neither Party may conduct any further Development or Commercialization activities with respect to the Product that gave rise to the Safety Concern until such Safety Concern is resolved; provided that if the Parties do not mutually agree how to resolve such Safety Concern within a [***] period, then Moderna shall have the right to determine whether there will be any further Development or Commercialization activities with respect to such Product, and the extent of those activities, including the right to cease or suspend or cause the cessation or suspension of the conduct of any ongoing or future Clinical Trials of the Product, and in the event Moderna determines that there will be no further Development or Commercialization activities with respect to the DT Co-Co Product in such DT Co-Co Program, the DT Co-Co Program shall terminate with respect to such DT Co-Co Product to the extent it has not already expired or been terminated otherwise, and the Parties shall cooperate with each other to wind-down their respective existing activities with respect to such Product.
Safety Concern. For purposes of this Agreement, “Safety Concern” means [***].
Safety Concern. If Capricor determines that the use of a CDC Product is likely to cause a clinical effect that is detrimental to the safety of patients, Capricor shall immediately notify JBI of such determination. The Parties shall meet and confer as soon as practicable regarding the facts leading to such determination and possible mitigation of such outcome.
